Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8697 - 8704 of 12086 results
Thirteen Ways to Contain Health Care Costs in Massachusetts: The Health Policy Commission Issues Its 2015 Report and Recommendations
January 27, 2016| Alert| Viewpoint
2016's TechBridge Challenge Focuses on Advanced Surfaces
January 27, 2016| Blog| Viewpoint
Massachusetts Health Care Reform – Full Speed Ahead; Health Policy Commission 2015 Cost Trends Report
January 27, 2016| Blog| Viewpoint
Federal Circuit Reverses Punitive Exceptional Case Fee Award as Improperly Enhanced
January 27, 2016| Advisory| Viewpoint
Drug Costs, Risk Adjustment Drive Q2 Health Insurance Rate Increases
January 26, 2016| Advisory| Viewpoint
Third Circuit Permits Chapter 11 Debtor to Reject Expired CBA
January 26, 2016| Blog| Viewpoint
Court Extends Vacatur on OPT Extensions for STEM Students
January 26, 2016| Alert| Viewpoint
Film Highlights National Security Need for Renewable Energy
January 26, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|